Slide 1: Investor Presentation Full Year 2022 results
For personal use only Investor Presentation Full Year 2022 results Treatment focused. Technology driven.
Slide 2: Disclaimer
Disclaimer For personal use only This document has been prepared as a summary only and does not contain all information about the Company’s assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company’s securities. This documen
Slide 3: Agenda
Agenda For personal use only • FY22 highlights • Vision and market opportunities • Financial information • Rest Assure® connected technology • Future outlook © August 2022 SomnoMed 3
Slide 4: FY22 highlights
For personal use only FY22 highlights
Slide 5: FY22 financial highlights
FY22 financial highlights For personal use only Total revenue EBITDA2 Cash A$72.6m A$1.3m A$15.6m +16% vs FY21 Delivered on FY22 Stable product gross Secured net $11m guidance margin of 70% in new debt funding North America EBITDA2 above guidance post FY22 +33% vs FY21 despite investment for Positiv
Slide 6: FY22 strategic & operational highlights
FY22 strategic & operational highlights For personal use only • Revenue momentum in FY22 demonstrates the strong fundamentals of the core business and the large growth opportunity for oral appliance solutions in the treatment of obstructive sleep apnea (OSA) • Strengthened sales and marketing effort
Slide 7: Digital manufacturing excellence
Digital manufacturing excellence Continued investment into digital manufacturing and engineering excellence to sustain expected milled For personal use only device growth, while driving enhanced quality foundations and continuous improvement capabilities • Quality - continue providing a 98% first-ti
Slide 8: Vision and market opportunity
For personal use only Vision and market opportunity
Slide 9: SomnoMed's vision and mission
SomnoMed’s vision and mission For personal use only Our vision is to lead in the treatment of patients suffering from obstructive sleep apnea and relevant adjacent conditions Our mission is to advance the adoption, acceptance and treatment of oral sleep apnea therapies by medical specialists, dentis
Slide 10: Significant addressable markets globally
Significant addressable markets globally Obstructive sleep apnea, a growing burden on the medical system affecting a significant portion of the population For personal use only Obstructive sleep apnea (OSA) is a disorder that occurs when a person’s breathing is interrupted during sleep because the a
Slide 11: Financial information
For personal use only Financial information
Slide 12: Total group revenues
Total group revenues $80m For personal use only +16% $72.6m $70m $62.7m $60m $50m +21% $40m +10% $38.6m $33.9m $30.8m $31.9m $30m $20m $10m $0m 1H 2H FY FY21 FY22 © August 2022 SomnoMed 12
Slide 13: Total regional revenues
Total regional revenues For personal use only North America Europe APAC $30m $45m +15% $6m +1% +33% 42.2 $40m 5.4 5.4 $25m $5m 24.7 $35m 36.8 $20m $30m $4m 18.5 +25% $25m +8% $15m $3m -5% +42% +5% 22.8 +25% $20m 2.8 2.7 2.6 12.8 19.5 2.6 11.9 18.6 18.2 $10m $15m $2m 9.5 9.0 $10m $5m $1m $5m $0m $0m
Slide 14: EBITDA and margin analysis / Product gross margin
EBITDA1 and margin analysis Product gross margin 70% 70% For personal use only • Gross margin grew by $6.5m vs FY21, reflecting increased revenues $39.5m driven by growth initiatives and improving engagement post COVID-19 $33.6m impacts • The MAS product gross margin of 70% remained stable for FY22
Slide 15: Profit and loss summary
Profit and loss summary For personal use only A$m FY22 FY21 % Regional sales and marketing expenses including: Revenue 72.6 62.7 +16% • $3m on sales and marketing resources to Gross margin 44.3 37.7 +17% drive organic growth as well as to support new product initiatives Regional sales & marketing ex
Slide 16: Summary balance sheet and cash flow
Summary balance sheet and cash flow For personal use only Statement of financial position Statement of cash flows A$m Statutory Statutory A$m Statutory Statutory 30 Jun 2022 30 Jun 2021 30 Jun 2022 30 Jun 2021 Cash and cash equivalents 15.6 21.1 EBITDA(1) 1.3 3.9 Inventories 3.1 2.3 Movement in work
Slide 17: Rest Assure: SomnoMed's technology-enabled oral appliance
For personal use only Rest Assure ® SomnoMed’s technology-enabled oral appliance
Slide 18: Rest Assure technology
® Rest Assure technology Smart oral appliance and cloud based infrastructure For personal use only SOM algorithms determine AHI1, graphs, tables Patient app Smart oral appliance with sensors recording overnight data. Physician portal Patient docks their device after Raw data transferred via Data tra
Slide 19: Patient study validation stage, best practice approach
Patient study validation 2 stage, best practice approach For personal use only Derivation of efficacy algorithm study: High correlation with NOX1 AHI2 (efficacy) • 30 patients (~480 hours of sleep) Rest Assure® vs NOX1 • Rest Assure® algorithms developed from output from NOX1 sleep test • Correlatio
Slide 20: Timeline for commercial readiness
Timeline for commercial readiness Rest Assure® - overnight compliance and efficacy monitoring for COAT™ For personal use only Delivered in FY22: • Finalise patent strategy • Present at World Sleep meeting (~3,000 physician attendees) • Completion of second patient validation study • Final design for
Slide 21: Future Outlook
For personal use only Future Outlook
Slide 22: Positioned for future growth
Positioned for future growth For personal use only Technology driven Investment in the technology pathway to unlock true COAT™ potential Best in class service and technical support Extensive and growing sales and distribution footprint in both dental and medical channels Treatment focused Design and
Slide 23: Clinical Research overview
Clinical Research overview SomnoMed remains committed to clinically validating our devices’ comfort, quality, compliance and efficacy For personal use only Future studies, conducted at some of the world’s leading medical institutions, are aimed at improving efficacy, adherence and the comfort of COA
Slide 24: Growing the sector through positioning the patient's alternative
Growing the sector through positioning the patient’s alternative For personal use only • Show sleep physicians how COAT™ and CPAP can be equally effective over a Effectiveness patient’s full night of sleep Equation • Focus is on superior compliance of COAT™ and patient preference for COAT™ • Fund an
Slide 25: Outlook
Outlook Advance the acceptance and adoption of technology enabled oral appliance treatment solution for OSA patients For personal use only FY23 guidance Operational initiatives Strategic objectives FY2026 aspiration2 • Revenue growth of at • Drive medical initiative • Remain patient centric • Over 1
Slide 26: For further information please contact
For personal use only For further information please contact: Corporate Investors Mr. Neil Verdal-Austin Mr. Craig Sainsbury CEO SomnoMed Automic Group +61 406 931 477 +61 428 550 499 Nverdal-austin@somnomed.com Craig.sainsbury@automicgroup.com.au © August 2022 SomnoMed 26